Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
AZ

AZRStock

Healthcare

$4.00 last close 2026-11-06
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment AZR's does — no target price to set, unlike a price alert.

Sharia status
NOT COMPLIANT
Per our in-house ratio engine
0 of 4 pass our own screen — 3 of 7 could not be computed
Purification 100.00% *
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure1 of 3 timeframes bullish · 28.6% aligned
VWAPPrice holding above VWAP ($4.00)

AZR is currently considered not halal (non-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

451 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →

Market & analysts
Price target
$13.00
+225.0% · 2 analysts
Institutional own.
25.9%
of shares
SMC grade
F · 29
28.6% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
F · 29
SMC grade — 28.6% timeframe alignment
$13.00
Price target (+225.0%) · 2 analysts
25.9%
Institutional ownership

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2025-12-31. These ratios come from the issuer's own published statements rather than structured SEC data.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail 1 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 2.07% 30.00% Pass
Interest-bearing investments 58.78% 30.00% Fail
Usmani Fail 1 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 6.22% 33.00% Pass
Interest-bearing investments 88.13% 33.00% Fail
Non-liquid assets 11.87% at least 20.00% Fail
MSCI Fail 1 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 3.11% 33.33% Pass
Cash + interest-bearing securities 88.13% 33.33% Fail
FTSE Fail 1 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 3.11% 33.33% Pass
Cash + interest-bearing securities 88.13% 33.33% Fail
Dow Jones Islamic Market Fail 1 of 2 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 2.67% 33.00% Pass
Cash + interest-bearing securities 75.77% 33.00% Fail
S&P Shariah Fail 1 of 2 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 3.05% 33.00% Pass
Cash + interest-bearing securities 86.45% 49.00% Fail
MSCI M-Series Fail 1 of 2 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 3.05% 33.33% Pass
Cash + interest-bearing securities 86.45% 33.33% Fail

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

Usmani (% of total assets)debt ratio 26.8pts
AAOIFI Standard 21 (% of market cap)debt ratio 27.9pts
S&P Shariah Indices (% of 36-mo avg market cap)debt ratio 30.0pts
Usmani (% of total assets)investments ratio 55.1pts
MSCI Islamic Index (% of total assets)cash and interest ratio 54.8pts
FTSE Shariah Global Equity Index Series (% of total assets)cash and interest ratio 54.8pts

The numbers the ratios are built from

Read from AZR's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $0 2025-12-31 yahoo:annualTotalRevenue
Interest-bearing debtShort and long-term borrowings $207.4K 2025-12-31 yahoo:annualTotalDebt
Cash and interest-bearing securitiesCash, equivalents and marketable securities $5.9M 2025-12-31 yahoo:annualCashCashEquivalentsAndShortTermInvestments
Total assetsBalance sheet total $6.7M 2025-12-31 yahoo:annualTotalAssets
Market capDenominator for AAOIFI $10.0M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series not measured — —
24-month average market capDenominator for Dow Jones Islamic Market not measured — —
Non-permissible revenueInterest and excluded income $149.6K 2025-12-31 yahoo:annualInterestIncome

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

What changed, and when

Verdict history for AZR. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for AZR has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

ℹ️ no compliance scan has run for 6 days - this is not a reading of today

8.256.534.813.081.362025-11-102026-05-122026-11-06

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
3.27
S2
3.49
S1
3.60
PIVOT
3.82
R1
3.93
R2
4.15
R3
4.26

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
2.09 – 5.53
±45.04% from 3.81, made 2026-11-01 · resolves 2026-11-08
STRONG SELL
from 19 indicators
61.9% of our last 5789 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 49.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

SELL
19 indicators
OscillatorsSTRONG BUY
3 buy · 4 neutral · 0 sell
Moving averagesSTRONG SELL
3 buy · 0 neutral · 9 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)49.10NEUTRAL
Stochastic %K (14)46.01NEUTRAL
CCI (20)13.19NEUTRAL
Williams %R (14)-53.99NEUTRAL
MACD (12,26,9)0.03BUY
ROC (10)2.04BUY
Momentum (10)0.08BUY
EMA (10)4.01SELL
SMA (10)4.09SELL
EMA (20)4.02SELL
SMA (20)3.85BUY
EMA (30)4.09SELL
SMA (30)3.92BUY
EMA (50)4.15SELL
SMA (50)4.50SELL
EMA (100)4.04SELL
SMA (100)4.04SELL
EMA (200)4.04SELL
SMA (200)3.18BUY

About AZR

Healthcare · Biotechnology

Azora Therapeutics, Inc. operates as a biopharmaceutical company that develops small molecule new chemical entities for the treatment of autoimmune and inflammatory diseases. It offers treatment for dermatology and gastroenterology. The company's pipeline includes AT177, a colon-targeted aryl hydrocarbon receptor (AhR) agonist to enable localized activation with limited systemic exposure in development for ulcerative colitis. Azora Therapeutics, Inc. was formerly known as Meya Pharmaceuticals, Inc. and changed its name to Azora Therapeutics, Inc. in March 2019. The company was incorporated in 2017 and is based in Encino, California.

azoratherapeutics.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

No real edge — avoid

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
🕐 1H RANGING 18
⏱ 15-Min BEARISH 73
⏲ 5-Min BULLISH 220

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-03 · Asset managers net 928584 (+5135)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.